Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Zepbound, the American firm’s weight-loss jab, was approved ... Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more effective drug, better execution, some keener pricing ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes ... Wegovy, although it contains the same drug, is approved for weight ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Lilly turned in strong first-quarter results, powered by its GLP-1 weight-loss drugs. But news about its Zepbound drug, along with lowered profit guidance, hurt the shares. The company's new oral ...

(Reuters) -A U.S. federal judge has sided with a U.S. regulator’s decision last year to take Eli Lilly’s blockbuster weight loss and diabetes drugs Zepbound ... U.S. Food and Drug ...